Cargando…

Increased Serum Soluble Urokinase-Type Plasminogen Activator Receptor (suPAR) Levels in FSGS: A Meta-Analysis

INTRODUCTION: The soluble urokinase-type plasminogen activator receptor (suPAR) has been found to be elevated in primary focal segmental glomerulosclerosis (pFSGS). However, its usefulness as a biomarker for FSGS remains controversial. We conducted a meta-analysis aiming at investigating the signifi...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Jiwon M., Yang, Jae Won, Kronbichler, Andreas, Eisenhut, Michael, Kim, Gaeun, Lee, Keum Hwa, Shin, Jae Il
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6476117/
https://www.ncbi.nlm.nih.gov/pubmed/31089477
http://dx.doi.org/10.1155/2019/5679518
_version_ 1783412849934073856
author Lee, Jiwon M.
Yang, Jae Won
Kronbichler, Andreas
Eisenhut, Michael
Kim, Gaeun
Lee, Keum Hwa
Shin, Jae Il
author_facet Lee, Jiwon M.
Yang, Jae Won
Kronbichler, Andreas
Eisenhut, Michael
Kim, Gaeun
Lee, Keum Hwa
Shin, Jae Il
author_sort Lee, Jiwon M.
collection PubMed
description INTRODUCTION: The soluble urokinase-type plasminogen activator receptor (suPAR) has been found to be elevated in primary focal segmental glomerulosclerosis (pFSGS). However, its usefulness as a biomarker for FSGS remains controversial. We conducted a meta-analysis aiming at investigating the significance of suPAR in diagnosing pFSGS. METHODS: Electronic databases (PubMed and EMBASE) were searched to identify studies comparing suPAR levels in FSGS patients and controls, from the earliest available date to May 1, 2018. A random-effects model with standardized mean difference (SMD) was used for meta-analyses. Risk of bias was assessed using the Newcastle-Ottawa quality assessment scale. RESULTS: A total of 187 articles were screened, and the final analysis included 13 articles. In comparison to healthy controls, serum suPAR levels were significantly increased in pFSGS patients (SMD, 1.07, 95% confidence interval (CI) 0.65 to 1.48; participants = 814; studies = 9, I (2) = 85%). Higher suPAR levels were also found in patients with pFSGS compared to those with minimal change disease (SMD 0.53, 95% CI 0.22 to 0.84). Of note, such a difference was not found in pediatric groups (SMD 0.42, 95% CI -0.13 to 0.96) while it was more evidently noted in adult patients (SMD 1.32, 95% CI 0.90 to 1.74). Serum suPAR levels did not differ between pFSGS patients in remission compared to those in active proteinuric state (SMD 0.29, 95% CI -0.30 to 0.88). Comparison with membranous nephropathy and IgA nephropathy showed no significant difference. CONCLUSIONS: Our meta-analysis demonstrated that, in comparison to both healthy controls and controls with minimal change disease, suPAR levels were significantly higher in adult patients with pFSGS. suPAR levels did not differ between pFSGS patients during the initial period of diagnosis and those in remission.
format Online
Article
Text
id pubmed-6476117
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-64761172019-05-14 Increased Serum Soluble Urokinase-Type Plasminogen Activator Receptor (suPAR) Levels in FSGS: A Meta-Analysis Lee, Jiwon M. Yang, Jae Won Kronbichler, Andreas Eisenhut, Michael Kim, Gaeun Lee, Keum Hwa Shin, Jae Il J Immunol Res Research Article INTRODUCTION: The soluble urokinase-type plasminogen activator receptor (suPAR) has been found to be elevated in primary focal segmental glomerulosclerosis (pFSGS). However, its usefulness as a biomarker for FSGS remains controversial. We conducted a meta-analysis aiming at investigating the significance of suPAR in diagnosing pFSGS. METHODS: Electronic databases (PubMed and EMBASE) were searched to identify studies comparing suPAR levels in FSGS patients and controls, from the earliest available date to May 1, 2018. A random-effects model with standardized mean difference (SMD) was used for meta-analyses. Risk of bias was assessed using the Newcastle-Ottawa quality assessment scale. RESULTS: A total of 187 articles were screened, and the final analysis included 13 articles. In comparison to healthy controls, serum suPAR levels were significantly increased in pFSGS patients (SMD, 1.07, 95% confidence interval (CI) 0.65 to 1.48; participants = 814; studies = 9, I (2) = 85%). Higher suPAR levels were also found in patients with pFSGS compared to those with minimal change disease (SMD 0.53, 95% CI 0.22 to 0.84). Of note, such a difference was not found in pediatric groups (SMD 0.42, 95% CI -0.13 to 0.96) while it was more evidently noted in adult patients (SMD 1.32, 95% CI 0.90 to 1.74). Serum suPAR levels did not differ between pFSGS patients in remission compared to those in active proteinuric state (SMD 0.29, 95% CI -0.30 to 0.88). Comparison with membranous nephropathy and IgA nephropathy showed no significant difference. CONCLUSIONS: Our meta-analysis demonstrated that, in comparison to both healthy controls and controls with minimal change disease, suPAR levels were significantly higher in adult patients with pFSGS. suPAR levels did not differ between pFSGS patients during the initial period of diagnosis and those in remission. Hindawi 2019-04-04 /pmc/articles/PMC6476117/ /pubmed/31089477 http://dx.doi.org/10.1155/2019/5679518 Text en Copyright © 2019 Jiwon M. Lee et al. http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Lee, Jiwon M.
Yang, Jae Won
Kronbichler, Andreas
Eisenhut, Michael
Kim, Gaeun
Lee, Keum Hwa
Shin, Jae Il
Increased Serum Soluble Urokinase-Type Plasminogen Activator Receptor (suPAR) Levels in FSGS: A Meta-Analysis
title Increased Serum Soluble Urokinase-Type Plasminogen Activator Receptor (suPAR) Levels in FSGS: A Meta-Analysis
title_full Increased Serum Soluble Urokinase-Type Plasminogen Activator Receptor (suPAR) Levels in FSGS: A Meta-Analysis
title_fullStr Increased Serum Soluble Urokinase-Type Plasminogen Activator Receptor (suPAR) Levels in FSGS: A Meta-Analysis
title_full_unstemmed Increased Serum Soluble Urokinase-Type Plasminogen Activator Receptor (suPAR) Levels in FSGS: A Meta-Analysis
title_short Increased Serum Soluble Urokinase-Type Plasminogen Activator Receptor (suPAR) Levels in FSGS: A Meta-Analysis
title_sort increased serum soluble urokinase-type plasminogen activator receptor (supar) levels in fsgs: a meta-analysis
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6476117/
https://www.ncbi.nlm.nih.gov/pubmed/31089477
http://dx.doi.org/10.1155/2019/5679518
work_keys_str_mv AT leejiwonm increasedserumsolubleurokinasetypeplasminogenactivatorreceptorsuparlevelsinfsgsametaanalysis
AT yangjaewon increasedserumsolubleurokinasetypeplasminogenactivatorreceptorsuparlevelsinfsgsametaanalysis
AT kronbichlerandreas increasedserumsolubleurokinasetypeplasminogenactivatorreceptorsuparlevelsinfsgsametaanalysis
AT eisenhutmichael increasedserumsolubleurokinasetypeplasminogenactivatorreceptorsuparlevelsinfsgsametaanalysis
AT kimgaeun increasedserumsolubleurokinasetypeplasminogenactivatorreceptorsuparlevelsinfsgsametaanalysis
AT leekeumhwa increasedserumsolubleurokinasetypeplasminogenactivatorreceptorsuparlevelsinfsgsametaanalysis
AT shinjaeil increasedserumsolubleurokinasetypeplasminogenactivatorreceptorsuparlevelsinfsgsametaanalysis